logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

On March 4, 2018,   Aimmune Therapeutics (AIMT)   – a biopharmaceutical company developing treatments for potentially life-threatening food allergies confirmed the superior news that brings hope to children and adults who are susceptible to peanut allergic reactions. The results...

Read More

March 5, 2018

0

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

Extremely important news has come from Montreal, Canada carrying the announcement by  Theratechnologies (TSX:TH)   and its partner TaiMed Biologics (TaiMed) that the FDA has granted approval of  Trogarzo™ (ibalizumab- uiyk) Injection . The approval is for Trogarzo to be...

Read More

March 8, 2018

0

Moderna Therapeutics: A Big Day Filled with Good News

Moderna Therapeutics Trial Results Moderna Therapeutics ( MRNA ) trial results mark the first systemic mRNA therapeutic to show the production of a secreted protein in humans.  Moderna's Product mRNA-1944 successfully encoded for functional antibody ( CHKV-24 ) in humans...

Read More

September 13, 2019

0

Atossa Genetics' news that staged a huge Rally of this small firm's stock

Atossa Genetics ( ATOS )  announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer...

Read More

March 14, 2019

0

The FDA approves the first ever postpartum depression product. Positive results from Dermira's atopic dermatitis product Lebrikizumab

News We Loved to Hear   The First and Only Approval of a Specific Product for Postpartum Depression ZULRESSO TM The FDA granted approval of Sage Therapeutics’ ( SAGE )  ZULRESSO TM (brexanolone) injection. A product for the treatment of...

Read More

March 20, 2019

0

Aimmune Therapeutics' product AR101 for the treatment of peanut allergy confirmed in Europe with previous successful results in the U.S.

While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as an unreadable market. Following the delivery of the Mueller report we hesitated to prophesy as we waited to see how the market would perform...

Read More

March 26, 2019

0

Could Incyte’s Ruxolitinib Cream Effectively Treat Vitiligo?

Vitiligo Vitiligo is a chronic autoimmune disease. The immune system attacks the pigment-producing melanocyte cells causing loss of skin pigmentation. This causes a skin discoloration condition known as vitiligo . The immune system’s attack affects around 0.2% to 2.0% of...

Read More

September 26, 2019

0

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares     CRISPRs  are bacterial immune systems that contain many defense enzymes such as the Cas9 “molecular scissors,” which scientists have engineered as  a   powerful DNA-targeting gene-editing tool  ...

Read More

March 28, 2018

0

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

Bellicum Pharmaceuticals (BLCM) :  The U.S. Food and Drug Administration (FDA) has l ifted the clinical hold on studies of BPX-501  in the U.S. The decision follows consultation with the FDA and agreement on amendments to the study protocols including guidance on monitoring and...

Read More

April 12, 2018

0

Let’s Go Shopping

In today’s news,  Incyte’s (INCY)  immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda ®  did not meet the endpoints of the trial in patients with unresectable or metastatic melanoma. The stock was subjected to a selloff...

Read More

April 6, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 65
  • 66
  • 67
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy